238 results on '"Paraproteinemias epidemiology"'
Search Results
2. Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study.
- Author
-
Siwiec-Kozlik A, Kozlik-Siwiec P, Spalkowska M, Korkosz M, and Kosalka-Wegiel J
- Subjects
- Humans, Retrospective Studies, Middle Aged, Female, Male, Adult, Aged, Paraproteinemias complications, Paraproteinemias mortality, Paraproteinemias epidemiology, Poland epidemiology, Cyclophosphamide therapeutic use, Prognosis, Prevalence, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic mortality, Lupus Erythematosus, Systemic drug therapy, Neoplasms mortality, Neoplasms complications, Neoplasms epidemiology
- Abstract
Objectives: Rheumatic diseases were previously associated with increased incidence of monoclonal gammopathy (MG) and its malignant transformation. The present study aimed to investigate the prevalence, malignant transformation risk, clinical correlates and prognostic impact of MG in SLE., Methods: A retrospective cohort study based on the medical records of n=1039 patients with SLE fulfilling the 1997 American College of Rheumatology (ACR), the 2019 European Alliance of Associations for Rheumatology (EULAR)/ACR and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria managed at two tertiary care departments of the University Hospital (Krakow, Poland) from January 2012 until November 2019., Results: SLE+MG cases were older at SLE diagnosis compared with non-MG SLE controls (53±15 years vs 37±15 years, respectively, p<0.01), had higher rates of lymphopenia, anaemia, haemolysis, serous effusions and interstitial lung disease (all p<0.05), and were more frequently treated with cyclophosphamide (57% vs 28%, p<0.01) or rituximab (13% vs 3%, p<0.01). Most MG cases were detected within a year after SLE diagnosis (Q25, Q75: 0, 12 years). With the median follow-up of 11 years (Q25, Q75: 6, 19 years), 34.8% (8 cases) of the SLE+MG cohort were diagnosed with malignancy, compared with 8.1% (82 cases) among the SLE controls (p<0.001). MG was associated with the relative hazard of death of HR 2.99 (95% CI 1.26 to 7.06, p<0.05) and a median survival time from SLE diagnosis to death of 5 years (Q25, Q75: 1, 14; range 0-41) for SLE+MG cases, as compared with 12 years (Q25, Q75: 6, 19; range 0-62) for the controls. The effect was non-independent on antimalarial medication use., Conclusions: Our study emphasises heightened malignancy and mortality rates in SLE+MG cases. The association between immunosuppression, MG incidence and progression warrants further research., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
3. Monoclonal gammopathy in the setting of Pyoderma gangrenosum.
- Author
-
Saeidi V, Garimella V, Shaji K, Wetter DA, Davis MDP, Todd A, Dutz J, and Alavi A
- Subjects
- Humans, Retrospective Studies, Middle Aged, Female, Male, Aged, Immunoglobulin A blood, Immunoglobulin A immunology, Adult, Immunoglobulin G blood, Immunoglobulin G immunology, Pyoderma Gangrenosum diagnosis, Pyoderma Gangrenosum epidemiology, Paraproteinemias complications, Paraproteinemias diagnosis, Paraproteinemias epidemiology, Paraproteinemias immunology
- Abstract
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterized by ulcerative painful lesions with violaceous undermined borders. Up to 75% of PG cases develop in association with an underlying systemic disease. Monoclonal gammopathy is reportedly a concomitant condition with PG, with studies indicating immunoglobulin (Ig) A gammopathy as the most common. Whether gammopathy is associated with PG or is an incidental finding has been debated. We sought to investigate the association and characteristics of gammopathy in patients with PG. We retrospectively identified PG patients at our institution from 2010 to 2022 who were screened for plasma cell dyscrasia. Of 106 patients identified, 29 (27%) had a gammopathy; subtypes included IgA (41%), IgG (28%), and biclonal (IgA and IgG) (14%). Mean age was similar between those with and without gammopathy (60.7 vs. 55.9 years; P = .26). In addition, hematologic or solid organ cancer developed in significantly more patients with vs. without gammopathy (8/29 [28%] vs. 5/77 [6%]; P = .003). Among the subtypes of gammopathy, IgG monoclonal gammopathy had the highest proportion of patients with subsequent cancer development (4 of 8 patients, 50%). Study limitations include a retrospective, single-institution design with a limited number of patients. Overall, our data show a high prevalence of gammopathy in patients with PG; those patients additionally had an increased incidence of cancer, especially hematologic cancer., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Sjögren's disease activity associates with cardiovascular disease and monoclonal gammopathy: a university cohort study of disease activity and comorbidities.
- Author
-
Bohman BR, Dowds HS, Blagogee TE, Ike RW, Hansen KE, and McCoy SS
- Subjects
- Humans, Cohort Studies, Universities, Severity of Illness Index, Comorbidity, Sjogren's Syndrome complications, Sjogren's Syndrome epidemiology, Sjogren's Syndrome diagnosis, Cardiovascular Diseases complications, Cardiovascular Diseases epidemiology, Paraproteinemias complications, Paraproteinemias epidemiology, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance epidemiology, Myocardial Infarction, Peripheral Vascular Diseases
- Abstract
Background: We used the University of Wisconsin cohort to determine the extent to which the EULAR Sjögren's syndrome disease activity index (ESSDAI) was associated with comorbidities that contribute to mortality., Methods: Our University of Wisconsin, Madison cohort had 111 patients with Sjögren's Disease (SjD) by 2016 ACR/EULAR criteria and 194 control patients with sicca. Our study was performed from March 1st, 2020 through April 1st, 2023. We collected data using a standardized collection tool, including components of the Charlson Comorbidity Index (CCI). Stratifying our SjD patients by ESSDAI < 5 and ESSDAI ≥ 5, we assessed differences in comorbidities associated with mortality., Results: At time of SjD diagnosis, the ESSDAI ≥ 5 group had increased odds of peripheral vascular disease compared to controls (OR 10.17; 95% CI 1.18-87.87). Patients with a current ESSDAI ≥ 5 were more likely to have a myocardial infarction compared to controls (OR 9.87; 95% CI 1.17-83.49). SjD patients had increased prevalence of monoclonal gammopathy compared to controls (9.3% vs 0.5%, p < 0.001). SjD patients with high ESSDAI at diagnosis had greater prevalence of monoclonal gammopathy compared to the SjD patients with a low ESSDAI (16% vs 5%, p = .04). As reported elsewhere, the ESSDAI ≥ 5 group had increased odds of chronic pulmonary disease (OR 4.37; 95% CI 1.59-11.97)., Conclusion: We found high ESSDAI scores were associated with worse cardiovascular outcomes, specifically peripheral vascular disease and myocardial infarction. Furthermore, monoclonal gammopathy was more frequent in SjD patients compared to sicca controls, supporting screening for monoclonal gammopathy in the appropriate clinical scenario. Key Points • High ESSDAI scores are associated with worse cardiovascular outcomes, specifically peripheral vascular disease and myocardial infarction. • Monoclonal gammopathy is more frequent in SjD patients than sicca controls, supporting screening for monoclonal gammopathy in the appropriate clinical scenario., (© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).)
- Published
- 2024
- Full Text
- View/download PDF
5. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
- Author
-
Sigurbergsdóttir AÝ, Rögnvaldsson S, Thorsteinsdóttir S, Sverrisdóttir I, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Gíslason GK, Ólafsson A, Hultcrantz M, Durie BGM, Harding S, Landgren O, Löve TJ, and Kristinsson SY
- Subjects
- Humans, Iceland, Comorbidity, Disease Progression, Multiple Myeloma diagnosis, Multiple Myeloma epidemiology, Multiple Myeloma complications, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor condition that precedes multiple myeloma and related disorders but has also been associated with other medical conditions. Since systematic screening is not recommended, MGUS is typically diagnosed due to underlying diseases and most cases are not diagnosed. Most previous studies on MGUS disease associations have been based on clinical cohorts, possibly resulting in selection bias. Here we estimate this selection bias by comparing clinically diagnosed and screened individuals with MGUS with regards to demographics, laboratory features, and comorbidities. A total of 75,422 participants in the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study were screened for MGUS by serum protein electrophoresis, immunofixation and free light chain assay (clinicaltrials gov. Identifier: NCT03327597). We identified 3,352 individuals with MGUS, whereof 240 had previously been clinically diagnosed (clinical MGUS), and crosslinked our data with large, nationwide registries for information on comorbidities. Those with clinical MGUS were more likely to have at least one comorbidity (odds ratio=2.24; 95% confidence interval: 1.30-4.19), and on average had more comorbidities than the screened MGUS group (3.23 vs. 2.36, mean difference 0.68; 95% confidence interval: 0.46-0.90). They were also more likely to have rheumatological disease, neurological disease, chronic kidney disease, liver disease, heart failure, or endocrine disorders. These findings indicate that individuals with clinical MGUS have more comorbidities than the general MGUS population and that previous studies have been affected by significant selection bias. Our findings highlight the importance of screening data when studying biological and epidemiological implications of MGUS.
- Published
- 2023
- Full Text
- View/download PDF
6. PARAKID: Navigating the relation between paraproteins and kidney lesions: A multi-center retrospective observational study.
- Author
-
Shankar M, Anandh U, and Guditi S
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Immunoglobulins, Kidney pathology, Paraproteins, Retrospective Studies, Kidney Diseases pathology, Multiple Myeloma complications, Paraproteinemias complications, Paraproteinemias epidemiology
- Abstract
Introduction: Monoclonal gammopathy is a heterogeneous group of disorders due to the clonal proliferation of immunoglobulin-producing plasma cells or B lymphocytes. Patients develop kidney disease not only due to malignant transformation but also due to the idiosyncratic properties of the M protein and the host factors. We aim to study the spectrum of kidney diseases in patients with paraproteinemia., Materials and Methods: A retrospective observational study was performed at three tertiary care centers in Southern India. Kidney biopsies conducted in these three centers were reviewed from June 1, 2020 to November 30, 2022. All biopsies suggestive of monotypic immunoglobulin or light chain restriction were included in the study., Results: A total of 122 patients were included in the study with an incidence of 2.4%. The mean age was 52.27 ± 13.27 years, and majority (63.1%) were males. AL amyloidosis was most common in the monoclonal gammopathy of renal significance (MGRS) group, and cast nephropathy was most common in the multiple myeloma (MM) group. On histopathology, 83.6% had a single lesion, followed by 14.8% with double lesion, and 1.6% with triple lesion., Conclusion: Paraproteinemia is associated with a myriad of kidney lesions. MGRS and MM are usually present in the 6
th decade of life and beyond, while proliferative glomerulonephritis with monoclonal immunoglobulin deposits is more common in the younger age group. Older age group, high creatinine, hyperuricemia, hyperphosphatemia, presence of more than one lesion on kidney biopsy, and presence of cast nephropathy was significantly associated with the requirement of kidney replacement therapy.- Published
- 2023
- Full Text
- View/download PDF
7. [Monoclonal gammopathy of uncertain significance].
- Author
-
Alejo E, Puertas B, and Mateos MV
- Subjects
- Humans, Middle Aged, Paraproteinemias complications, Paraproteinemias diagnosis, Paraproteinemias epidemiology, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Multiple Myeloma complications
- Abstract
Monoclonal gammopathy of uncertain significance is a premalignant plasma cell neoplasm with a high prevalence in the population over 50 years of age and an annual risk of progression of 1%. Multiple recent studies have led to advances in understanding both the pathogenesis of these disorders and their risk of progression to other diseases. Patients require lifelong follow-up, and a multidisciplinary and risk-adapted approach is essential. In recent years, an increasing number of entities associated with a paraprotein, known as clinically significant monoclonal gammopathies, have been recognized., (Copyright © 2023. Published by Elsevier España, S.L.U.)
- Published
- 2023
- Full Text
- View/download PDF
8. Biclonal Gammopathies in South Tunisia: Clinical and Biological Characteristics.
- Author
-
Jerbi A, Hachicha H, Charfi A, Kallel F, Feki S, Ben Ayed M, Ayadi F, Akrout R, Frikha F, Amouri A, Kammoun K, Mdhaffar M, Ben Hmida M, Tahri N, Bahloul Z, Baklouti S, Elloumi M, and Masmoudi H
- Subjects
- Humans, Middle Aged, Aged, Aged, 80 and over, Retrospective Studies, Tunisia epidemiology, Immunoglobulin G, Paraproteinemias epidemiology, Multiple Myeloma epidemiology, Multiple Myeloma complications
- Abstract
Objective: Biclonal gammopathies (BGs) are rare situations characterized by the production of 2 monoclonal proteins. There are no available data on BGs in North Africa. We aimed to estimate the prevalence of BGs in our population and describe their clinical and laboratory features., Methods: We conducted a 31-year retrospective study including patients with persistent double monoclonal bands based on the results of immunofixation/immunoelectrophoresis., Results: A total of 35 patients with available clinical data (sex ratio, M/F = 1.53; mean age, 70 ± 10.87 years [range, 45-90 years]) were included. The main associated conditions were multiple myeloma (MM) (40%), BG of undetermined significance (BGUS) (34%), and lymphoproliferative diseases (23%). Only one-third of the patients had 2 monoclonal spikes on serum protein electrophoresis. The most common paraprotein combinations were immunoglobulin (Ig)G-IgG (25%) and IgG-IgA (23%) with different light chains in one-half of the cases. The mean follow-up was 25.6 months (median, 12 months). No BGUS evolved into a malignant disease., Conclusion: BGs are rare in clinical laboratory routine but must be accurately identified by the pathologist. Our cohort is characterized by a high prevalence of BGUS compared with MM., (© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
9. Epidemiology of monoclonal gammopathy in Morocco - A hospital-based study.
- Author
-
Ouzzif Z, Doghmi K, Messaoudi N, Bouhsain S, El Machtani S, Biaz A, Rachid A, Dami A, Bezza A, and El Maataoui A
- Subjects
- Male, Humans, Female, Middle Aged, Aged, Morocco epidemiology, Retrospective Studies, Hospitals, Paraproteinemias epidemiology, Paraproteinemias diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Monoclonal Gammopathy of Undetermined Significance diagnosis, Multiple Myeloma diagnosis, Multiple Myeloma epidemiology, Waldenstrom Macroglobulinemia epidemiology
- Abstract
Background: Monoclonal gammopathies are a group of disorders associated with clonal proliferation of plasma cells that produces a monoclonal protein., Aims: The main objective of this study was to describe the epidemiological and immunochemical characteristics of monoclonal gammopathies diagnosed during 19 years in a Moroccan teaching hospital., Materials and Results: This retrospective study enrolled 443 Moroccan patients with monoclonal gammopathy, patients meeting the inclusion and exclusion criteria in at the biochemistry department of Military Hospital in Rabat, the capital of Morocco, from January 2000 to August 2019. Of the 443 enrolled patients, 320 (72.23%) were men and 123 (27.77%) were women. All patients were of Caucasian origin, from 12 Moroccan regions. The patient's samples were collected and subjected to serum protein electrophoresis and serum immunofixation electrophoresis to further characterize the monoclonal protein. The mean ± SD age of the 443 participants was 62.24 ± 13.14 years. Reasons for being admitted to the hospital were as follows, bone pain (41.60%), renal failure (19.08%), alteration of the general condition (12.21%), and anemia (10.69). Plasma cell proliferative disorders in our study were as follows, multiple myeloma (MM) (45.65%), Monoclonal gammopathies of undetermined significance (MGUS) (39.05%), Waldenstrom's macroglobulinemia (5.58%), Lymphoma (2.27% + 1.2%), Chronic Lymphocytic Leukemia (2.48%), Plasma cell leukemia (1.86%), Plasmacytoma (0.62%), POEMS syndrome (0.41%), and Amyloidosis (0.84%). The most frequent isotypes in MM were the IgGκ (62) 36.5%, IgGλ (52) 30.6%, IgAκ (27) 15.9%, and the IgAλ (19) 11.2%. It is also worth noting that Free light chain MM represents 20% of all cases of MM., Conclusions: We found that monoclonal gammopathies are age-related and affects men more than women, also the results of this study point to the delayed diagnosis of monoclonal gammopathies, since most of our patients were diagnosed at the MM stage. The most frequent isotypes were the IgGκ and IgGλ in MM and MGUS, in Waldenström macroglobulinemia were IgMκ and IgMλ and the oligoclonal profile represented only 3.70%., (© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
10. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.
- Author
-
Cicero KI, Joffe M, Patel M, Chiuzan C, Pentz A, Ruff P, Lentzsch S, Leng S, Jacobson JS, Rebbeck TR, and Neugut AI
- Subjects
- Male, Humans, Prevalence, South Africa epidemiology, Immunoglobulin Light Chains, Risk Factors, Monoclonal Gammopathy of Undetermined Significance epidemiology, Monoclonal Gammopathy of Undetermined Significance complications, Paraproteinemias epidemiology, Paraproteinemias complications, Multiple Myeloma
- Abstract
Background: Both multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance (MGUS), occur twice as often within Black compared with White populations, suggesting that racial disparities lie within the development of MGUS. Nonetheless, MGUS has been studied mainly in White cohorts; the study that first described the natural history of MGUS was conducted in 97.3% White Olmsted County, Minnesota., Methods: We determined the prevalence of MGUS among 386 Black South African (SA) men >30 years at Chris Hani Baragwanath Hospital in Johannesburg. We conducted serum protein electrophoresis and free light chain quantification to define MGUS by the same criteria as the Olmsted County studies. We also investigated the association between MGUS and various clinical factors, including human immunodeficiency virus (HIV) infection and smoking., Results: We found the prevalence of MGUS to be 8.03% [95% confidence interval (CI), 5.32-10.74], nearly 1.6-fold higher than in the White Olmsted County male population. In a univariable logistic regression model, MGUS was associated with HIV status (OR, 2.39; 95% CI, 0.95-5.49), but in an adjusted model that included body mass index and cigarette use, the association was not statistically significant. Those who were current (vs. never) cigarette smokers were more likely to have MGUS in both univariable (OR, 5.60; 95% CI, 2.16-17.42) and multivariable models (OR, 4.49; 95% CI, 1.63-14.56)., Conclusions: The prevalence of MGUS in Black SA men is substantially higher than in White populations and may be associated with HIV status and cigarette use., Impact: Racial disparities in MGUS exist and may be associated with potentially modifiable risk factors., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
11. Prevalence of corneal findings and their interrelation with hematological findings in monoclonal gammopathy.
- Author
-
Al Hariri M, Munder M, Lisch W, Schuster AK, Fehr EM, Jacobi B, Desuki A, Kreft A, Gericke A, Pfeiffer N, and Wasielica-Poslednik J
- Subjects
- Humans, Prevalence, Vision Disorders, Corneal Diseases diagnosis, Corneal Opacity, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias epidemiology
- Abstract
Purpose: To determine prevalence of paraproteinemic keratopathy (PPK) among patients with monoclonal gammopathy (MG). To evaluate interrelation between corneal and hematological parameters in patients with PPK., Methods: Fifty-one patients with monoclonal gammopathy of undetermined significance (n = 19), smoldering multiple myeloma (n = 5) or multiple myeloma (n = 27) were prospectively included in this study. Best-corrected visual acuity, slit-lamp biomicroscopy, Scheimpflug tomography, in-vivo confocal laser scanning microscopy, optical coherence tomography and complete hematological workup were assessed., Results: We identified n = 19 patients with bilateral corneal opacities compatible with PPK. PPK was newly diagnosed in 13 (29%) of 45 patients with a primary hematological diagnosis and in n = 6 patients without previous hematological diagnosis. The most common form was a discreet stromal flake-like PPK (n = 14 of 19). The median level of M-protein (p = 0.59), IgA (p = 0.53), IgG (p = 0.79) and IgM (p = 0.59) did not differ significantly between the patients with and without PPK. The median level of the FLC κ in serum of patients with kappa-restricted plasma cell dyscrasia was 209 mg/l in patients with PPK compared to 38.1 mg/l in patients without PPK (p = 0.18). Median level of FLC lambda in serum of patients with lambda-restricted plasma cell dyscrasia was lower in patients with PPK compared to patients without PPK (p = 0.02)., Conclusion: The PPK was mostly discreet, but its prevalence (29%) was higher than expected. Median level of the monoclonal paraprotein was not significantly higher in patients with PPK compared to patients without PPK. Our results suggest a lack of correlation between morphology and severity of the ocular findings and severity of the monoclonal gammopathy., Trial Registration: German Clinical Trial Register: DRKS00023893., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
12. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
- Author
-
Martins M, Bridoux F, Goujon JM, Meuleman MS, Ribes D, Rondeau E, Guerry MJ, Delmas Y, Levy B, Ducloux D, Kandel-Aznar C, Le Fur A, Garrouste C, Provot F, Gibier JB, Thervet E, Bruneval P, Rabant M, Karras A, Dragon Durey MA, Fremeaux-Bacchi V, and Chauvet S
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, Complement Activation, Complement System Proteins, Humans, Retrospective Studies, Atypical Hemolytic Uremic Syndrome epidemiology, Atypical Hemolytic Uremic Syndrome genetics, Paraproteinemias complications, Paraproteinemias epidemiology, Thrombotic Microangiopathies epidemiology, Thrombotic Microangiopathies etiology
- Abstract
Rationale & Objective: Hemolytic uremic syndrome (HUS), a thrombotic microangiopathy (TMA) with kidney involvement, is a rare condition in patients with monoclonal gammopathy. In the absence of known causes of TMA, the role of complement activation in endothelial injury in patients with monoclonal gammopathy remains unknown and was the focus of this investigation., Study Design: Case series., Setting & Participants: We studied the 24 patients in the French national registry of HUS between 2000 and 2020 who had monoclonal gammopathy without other causes of secondary TMA. We provide the clinical histories and complement studies of these patients., Findings: Monoclonal gammopathy-associated TMA with kidney involvement is estimated to be 10 times less frequent than adult atypical HUS (aHUS) in the French national registry. It is characterized by severe clinical features, with 17 of 24 patients requiring dialysis at disease onset, and with median renal survival of only 20 months. TMA-mediated extrarenal manifestations, particularly cutaneous and neurological involvement, were common and associated with poor overall prognosis. Complement studies identified low C3, normal C4, and high soluble C5b-9 levels in 33%, 100%, and 77% of tested patients, respectively, indicating a contribution of the alternative and terminal complement pathways in the pathophysiology of the disease. Genetic abnormalities in complement genes known to be associated with aHUS were found in only 3 of 17 (17%) who were tested., Limitations: Retrospective study without comparison group; limited number of patients, limited available blood samples., Conclusions: Within the spectrum of TMA, TMA associated with monoclonal gammopathy represents a distinct subset. Our findings suggest that HUS associated with monoclonal immunoglobulin is a complement-mediated disease akin to aHUS., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
13. Prevalence of monoclonal gammopathy of undetermined significance in US black women.
- Author
-
Bertrand KA, Zirpoli G, Niharika Pillalamarri B, Szalat R, Palmer JR, and Kataria Y
- Subjects
- Female, Humans, Prevalence, Monoclonal Gammopathy of Undetermined Significance epidemiology, Multiple Myeloma, Paraproteinemias epidemiology
- Published
- 2022
- Full Text
- View/download PDF
14. Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance.
- Author
-
Castañeda-Avila MA, Lapane KL, Person SD, Zhou Y, Gurwitz J, Mazor KM, and Epstein MM
- Subjects
- Aged, Biomarkers, Comorbidity, Disease Progression, Humans, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Abstract
Understanding the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is needed to identify patients who would benefit from closer clinical surveillance. Given that two of the defining criteria of MM are renal failure and anemia, we described the trajectories of creatinine (Cr) and hemoglobin (Hgb) over time in patients with a diagnosis of MGUS. Patients diagnosed with MGUS (n = 424) were identified by a previously validated case-finding algorithm using health claims and electronic health record data (2007-2015) and followed through 2018. Group-based trajectory modeling identified patients with distinct laboratory value trajectories of Cr (mg/dl) and Hgb (g/dl). Most patients were non-Hispanic White (97.6%) with a mean age of 75 years at MGUS diagnosis. Three multi-trajectory groups were identified: (1) Normal Cr/Hgb (n = 225; 53.1%)-stable serum Cr levels and decreasing, normal Hgb levels; (2) Normal Cr/lower-normal Hgb group (n = 188; 44.3%)-stable, slightly elevated levels of Cr and decreasing levels of Hgb; and (3) High Cr/borderline Hgb group (n = 11; 2.6%)-increased Cr levels and stable low levels of Hgb. Patients with MGUS in Group 2 were older than patients in other groups, and patients in group 3 had more comorbidities than participants in all other groups. Few patients developed MM during the study period. We were able to identify distinct biomarker trajectories in patients with MGUS over time. Future research should investigate how these trajectories may be related to the risk of progression to MM, including M-protein levels., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
15. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
- Author
-
El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, and Ghobrial IM
- Subjects
- Cohort Studies, Female, Humans, Male, Mass Spectrometry, Prevalence, Monoclonal Gammopathy of Undetermined Significance epidemiology, Multiple Myeloma epidemiology, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Abstract
Background: Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of European ancestry aged 50 years or older. MGUS prevalence is two times higher in individuals of African descent or with a family history of conditions related to multiple myeloma. We aimed to evaluate the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population screened by quantitative mass spectrometry., Methods: We used quantitative matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry and EXENT-iQ software to screen for and quantify monoclonal gammopathies in serum from 7622 individuals who consented to the PROMISE screening study between Feb 26, 2019, and Nov 4, 2021, and the Mass General Brigham Biobank (MGBB) between July 28, 2010, and July 1, 2021. M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were confirmed by liquid chromatography mass spectrometry testing. 6305 (83%; 2211 from PROMISE, 4094 from MGBB) of 7622 participants in the cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a family history of haematological malignancies and fell within the eligible high-risk age range (30 years or older for PROMISE cohort and 18 years or older for MGBB cohort); those over 18 years were also eligible if they had two or more family members with a blood cancer (PROMISE cohort). Participants with a plasma cell malignancy diagnosed before screening were excluded. Longitudinal clinical data were available for MGBB participants with a median follow-up time from serum sample screening of 4·5 years (IQR 2·4-6·7). The PROMISE study is registered with ClinicalTrials.gov, NCT03689595., Findings: The median age at time of screening was 56·0 years (IQR 46·8-64·1). 5013 (66%) of 7622 participants were female, 2570 (34%) male, and 39 (<1%) unknown. 2439 (32%) self-identified as Black, 4986 (65%) as White, 119 (2%) as other, and 78 (1%) unknown. Using serum protein electrophoresis with immunofixation electrophoresis, the MGUS prevalence was 6% (101 of 1714) in high-risk individuals aged 50 years or older. Using mass spectrometry, we observed a total prevalence of monoclonal gammopathies of 43% (1788 of 4207) in this group. We termed monoclonal gammopathies below the clinical immunofixation electrophoresis detection level (<0·2 g/L) MGIPs, to differentiate them from those with higher concentrations, termed mass-spectrometry MGUS, which had a 13% (592 of 4207) prevalence by mass spectrometry in high-risk individuals aged 50 years or older. MGIP was predominantly of immunoglobulin M isotype, and its prevalence increased with age (19% [488 of 2564] for individuals aged <50 years, 29% [1464 of 5058] for those aged ≥50 years, and 37% [347 of 946] for those aged ≥70 years). Mass-spectrometry MGUS prevalence increased with age (5% [127 of 2564] for individuals aged <50 years, 13% [678 of 5058] for those aged ≥50 years, and 18% [173 of 946] for those aged ≥70 years) and was higher in men (314 [12%] of 2570) compared with women (485 [10%] 5013; p=0·0002), whereas MGIP prevalence did not differ significantly by gender. In those aged 50 years or older, the prevalence of mass spectrometry was significantly higher in Black participants (224 [17%] of 1356) compared with the controls (p=0·0012) but not in those with family history (368 [13%] of 2851) compared with the controls (p=0·1008). Screen-detected monoclonal gammopathies correlated with increased all-cause mortality in MGBB participants (hazard ratio 1·55, 95% CI 1·16-2·08; p=0·0035). All monoclonal gammopathies were associated with an increased likelihood of comorbidities, including myocardial infarction (odds ratio 1·60, 95% CI 1·26-2·02; p=0·00016 for MGIP-high and 1·39, 1·07-1·80; p=0·015 for mass-spectrometry MGUS)., Interpretation: We detected a high prevalence of monoclonal gammopathies, including age-associated MGIP, and made more precise estimates of mass-spectrometry MGUS compared with conventional gel-based methods. The use of mass spectrometry also highlighted the potential hidden clinical significance of MGIP. Our study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival., Funding: Stand Up To Cancer Dream Team, the Multiple Myeloma Research Foundation, and National Institutes of Health., Competing Interests: Declaration of interests DS, DB, MCP are current employees of The Binding Site. MB is a consultant for Takeda and has received honoraria from Takeda, Janssen, and Bristol Myers Squibb (BMS). SH is a current employee, member of the Board of Directors, and holds patents related to The Binding Site. CCM is a consultant for Eli Lilly and Epizyme, is an advisory board member for BMS, has served as a consultant and advisory board member for GlaxoSmithKline (GSK), has received honoraria from Janssen, Karyopharm, and Sanofi; and served as an advisory board member for Karyopharm and Sanofi. PK is a principal investigator of studies for which Mayo Clinic has received research funding from AbbVie, Sanofi, Amgen, GSK, Ichnos, Takeda, Regeneron, and Karyopharm; and has received honoraria from X4 pharmaceuticals, Beigene, Pharmacyclics, Imidex, Clinical Care Options, GSK, Oncopeptides, Cellectar, and Karyopharm. JM is a consultant for Amgen, BMS, GSK, Janssen, Karyopharm, Sanofi, and Takeda. RF is a consultant for AbbVie, Amgen, Bayer, BMS/Celgene, GSK, H3 Therapeutics, Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Oncopeptides, OncoTracker, Pfizer, Pharmacyclics, Regeneron, Sanofi, and Takeda; and is on scientific advisory board of Adaptive Biotechnologies, Caris Life Sciences, OncoMyx, and OncoTracker. GG receives research funds from International Business Machines Corporation and Pharmacyclics and is an inventor on patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER, SignatureAnalyzer-GPU and TensorQTL. GG is a founder, consultant and holds privately held equity in Scorpion Therapeutics. CRM has serves as a consultant for JBF Legal and received research funding from GRAIL. IMG has served as a consultant for AbbVie, Adaptive, Aptitude Health, BMS, Cellectar, CurioScience, Genetch, Janssen, Janssen Central American and Caribbean, Karyopharm, Medscape, Oncopeptides, Sanofi, Takeda, The Binding Site, Gene Network Sciences Healthcare, and GSK. IMG's spouse, William Savage is CMO and equity holder at Disc Medicine. All other authors declare no competing interest., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
16. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
- Author
-
Kleinstern G, Larson DR, Allmer C, Norman AD, Muntifering G, Sinnwell J, Visram A, Rajkumar V, Dispenzieri A, Kyle RA, Slager SL, Kumar S, and Vachon CM
- Subjects
- Body Mass Index, Disease Progression, Female, Humans, Male, Minnesota epidemiology, Risk Factors, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Multiple Myeloma complications, Paraproteinemias epidemiology
- Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m
2 < 25/≥25) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI ≥ 25 versus BMI < 25 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0-25), while 465 patients died and 57 progressed and developed MM (N = 39), AL amyloidosis (N = 8), lymphoma (N = 5), or Waldenstrom-macroglobulinemia (N = 5). In univariate analyses, BMI ≥ 25 (HR = 2.14,CI:1.05-4.36, P = 0.04), non-IgG (HR = 2.84, CI:1.68-4.80, P = 0.0001), high monoclonal (M) protein (HR = 2.57, CI:1.50-4.42, P = 0.001), and abnormal free light chain ratio (FLCr ) (HR = 3.39, CI:1.98-5.82, P < 0.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic = 0.75, CI:0.68-0.82). The BMI association was stronger among females (HR = 3.55, CI:1.06-11.9, P = 0.04) vs. males (HR = 1.39, CI:0.57-3.36, P = 0.47), although the interaction between BMI and sex was not significant (P = 0.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLCr . This association may be stronger among females., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
17. The consequences of COVID-19 pandemic on patients with monoclonal gammopathy-associated systemic capillary leak syndrome (Clarkson disease).
- Author
-
Pineton de Chambrun M, Moyon Q, Faguer S, Urbanski G, Mathian A, Zucman N, Werner M, Luyt CE, Verlicchi F, and Amoura Z
- Subjects
- Humans, Pandemics, SARS-CoV-2, COVID-19, Capillary Leak Syndrome diagnosis, Capillary Leak Syndrome epidemiology, Paraproteinemias complications, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Published
- 2022
- Full Text
- View/download PDF
18. [Descriptive cross-sectional study assessing the clinical and paraclinic profiles of monoclonal gammopathies in an agricultural region of Souss-Massa, Morocco].
- Author
-
Maataoui AE, Taoufiq A, Fares S, and Sokori K
- Subjects
- Adolescent, Cross-Sectional Studies, Female, Humans, Male, Morocco epidemiology, Retrospective Studies, Delayed Diagnosis, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Abstract
Introduction: given the lack of information about monoclonal gammopathies, our primary study outcome was to describe the epidemiological, clinical and biochemical profiles of monoclonal gammopathies in the Souss-Massa region, in southern Morocco., Methods: we conducted a retrospective study, by selecting only complete medical records. We used records of patients diagnosed with monoclonal gammopathy at the local oncology center during a period of over 10 years., Results: one hundred and seventeen patients were included in the study, with a high male predominance (65%) and a male/female sex-ratio of 1.85. The average age of our study population was 61.44 (ET 14.54) years. Diagnoses (based on frequency) included: multiple myeloma 82.0% (n=96), solitary plasmacytoma 8.5% (n=10), monoclonal gammopathies of undetermined significance 2.6% (n=3), lymphoma 2.5% (n=3), secondary plasma cell leukaemia 1.7% (n=2), Waldenström´s disease 1.7%(n=2) and chronic lymphoid leukemia (n=1). The isotype distribution was as follows: IgG Kappa 33.7% (n=28), IgG lambda 21.7% (n=18), IgA Kappa 12.0% (n=10), IgA lambda 7.2% (n=6), IgM kappa 3.6% (n=3), and IgD lambda 2.4% (n=2). Biconal peak was reached in two cases, with a percentage of 2.4%., Conclusion: diagnostic delay was observed compared to international studies due to the unavailability of electrophoresis in the care structures., Competing Interests: Les auteurs ne déclarent aucun conflit d´intérêts., (Copyright: Aissam El Maataoui et al.)
- Published
- 2022
- Full Text
- View/download PDF
19. Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia.
- Author
-
Berger T, Shacham Abulafia A, Shimony S, Pasvolsky O, Vaxman I, Miron Y, Feldman S, Leader A, and Raanani P
- Subjects
- Humans, Middle Aged, Prevalence, Cross-Sectional Studies, Multiple Myeloma diagnosis, Paraproteinemias complications, Paraproteinemias epidemiology, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology
- Abstract
Introduction: Data regarding the prevalence of paraproteinemia in patients with chronic myeloid leukemia (CML) are lacking., Methods: To evaluate for the prevalence of paraproteinemia, we undertook this cross-sectional study among consecutive chronic-phase CML patients. Complete blood count, chemistry, immunoglobulins, serum-free light chains, serum-protein electrophoresis and immunofixation were collected. Further analyses evaluated whether various patient-, disease-, and treatment-related variables are associated with paraproteinemia., Results: One hundred patients, median age 63.5 (IQR 48.1-72) years were recruited. Median time from CML diagnosis to enrollment was 6.3 (IQR 2.3-11.3) years. Monoclonal protein was detected in 8 patients (8%), diagnosed with smoldering multiple myeloma (SMM, n = 2) and low-risk monoclonal gammopathy of undetermined significance (MGUS, n = 6). Six patients were on tyrosine kinase inhibitor treatment, 2 were in treatment-free remission. The only covariate associated with paraproteinemia was the presence of anemia, albeit with borderline statistical significance in univariate analysis (p = 0.053) and when adjusted for age (p = 0.056)., Conclusions: In this largest study so far describing the prevalence of paraproteinemia among CML patients, we found MGUS prevalence to be higher than the 3.2% expected prevalence in the general population above 50 years and a non-negligible prevalence of SMM (2%). Screening for paraproteinemia in CML patients, especially in the presence of anemia, should be considered., (© 2022 S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF
20. Immunotyping Provides Equivalent Results to Immunofixation in a Population with a High Prevalence of Monoclonal Gammopathies.
- Author
-
Thoren KL, McCash SI, and Murata K
- Subjects
- Antibodies, Monoclonal, Humans, Immunoelectrophoresis, Immunoglobulin Light Chains, Prevalence, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Abstract
Background: Serum immunofixation (IF) is a common laboratory test used to diagnose and monitor patients with monoclonal gammopathies. Similarly, immunotyping (IT) by capillary electrophoresis can confirm the presence of a monoclonal protein (M-protein) and determine its isotype. The goal of this study was to compare the ability of IT and IF to detect M-proteins., Methods: IT and IF results for 1000 waste clinical serum samples were obtained. All results were interpreted blindly by reviewers who were experienced in each technique. Results were compared by band. Results were also compared to patient history to determine if the original clone was present. We determined the sensitivity of IT and IF alone and in combination with additional tests. Finally, we evaluated the impact of reviewer training on the sensitivity of IT., Results: IT and IF were concordant in 721/773 (93%) samples with a history of an intact M-protein and in 143/172 (83%) samples with a history of a free light chain (FLC) M-protein. IF was significantly more sensitive than IT for the detection of FLC M-proteins (P < 0.0001). However, IF was not more sensitive than IT for detection of intact M-proteins (P = 0.1272) or when each test was combined with the FLC ratio or urine immunofixation (P = 0.2812 and P = 0.6171, respectively). Finally, after training, inexperienced reviewers improved their IT sensitivity by 19%., Conclusion: IT provides equivalent results to IF for the detection of monoclonal proteins. Training and experience are critical to the accurate interpretation of IT., (© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
21. Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience.
- Author
-
Matà S, Torricelli S, Barilaro A, Grippo A, Forleo P, Del Mastio M, and Sorbi S
- Subjects
- Humans, Immunoglobulin M, Myelin-Associated Glycoprotein, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Paraproteinemias complications, Paraproteinemias epidemiology, Peripheral Nervous System Diseases, Polyneuropathies epidemiology
- Abstract
Background and Purpose: Polyneuropathies associated with monoclonal gammopathy of undetermined significance (MGUS) encompass a group of phenotypically and immunologically heterogeneous neuropathies. While the best characterized is that associated with anti-myelin glycoprotein (MAG) antibodies, there are phenotypical and immunological neuropathy variants that still lack a clear classification. We analyzed a significant number of patients, in order to better evaluate the distribution of neuropathy phenotypes and to look for some common characteristics., Methods: Clinical, neurophysiological, and laboratory data from 87 consecutive MGUS patients with peripheral neuropathy were analyzed and compared among patient groups with different MGUS classes and autoantibody reactivity., Results: Anti-MAG neuropathy cases account for the most homogeneous group with regard to clinical and neurophysiological findings. Patients with anti-gangliosides or sulfatide (GS) antibodies, despite a marked phenotype heterogeneity, still share several common features, including a younger age at diagnosis, a more severe disease, and a prompt and sustained response to both immunoglobulin and rituximab therapies, mostly requiring chronic administration of immune treatment., Conclusions: Although heterogeneous, MGUS-associated, anti-GS antibody positive neuropathies have important similar features possibly resulting from a similar biological background., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Screening for Gaucher disease among patients with plasma cell dyscrasias.
- Author
-
Ntanasis-Stathopoulos I, Gavriatopoulou M, Fotiou D, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Kastritis E, Dimopoulos MA, and Terpos E
- Subjects
- Humans, Gaucher Disease complications, Gaucher Disease diagnosis, Gaucher Disease epidemiology, Paraproteinemias complications, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Published
- 2021
- Full Text
- View/download PDF
23. Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort.
- Author
-
Lamb MJ, Smith A, Painter D, Kane E, Bagguley T, Newton R, Howell D, Cook G, de Tute R, Rawstron A, Patmore R, and Roman E
- Subjects
- B-Lymphocytes, Humans, United Kingdom epidemiology, Lymphocytosis epidemiology, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Multiple Myeloma, Paraproteinemias epidemiology
- Abstract
Objective: To examine mortality and morbidity patterns before and after premalignancy diagnosis in individuals with monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL) and compare their secondary healthcare activity to that of the general population., Design: Population-based patient cohort, within which each patient is matched at diagnosis to 10 age-matched and sex-matched individuals from the general population. Both cohorts are linked to nationwide information on deaths, cancer registrations and Hospital Episode Statistics., Setting: The UK's Haematological Malignancy Research Network, which has a catchment population of around 4 million served by 14 hospitals and a central diagnostic laboratory., Participants: All patients newly diagnosed during 2009-2015 with MGUS (n=2193) or MBL (n=561) and their age and sex-matched comparators (n=27 538)., Main Outcome Measures: Mortality and hospital inpatient and outpatient activity in the 5 years before and 3 years after diagnosis., Results: Individuals with MGUS experienced excess morbidity in the 5 years before diagnosis and excess mortality and morbidity in the 3 years after diagnosis. Increased rate ratios (RRs) were evident for nearly all clinical specialties, the largest, both before and after diagnosis, being for nephrology (before RR=4.29, 95% CI 3.90 to 4.71; after RR=13.8, 95% CI 12.8 to 15.0) and rheumatology (before RR=3.40, 95% CI 3.18 to 3.63; after RR=5.44, 95% CI 5.08 to 5.83). Strong effects were also evident for endocrinology, neurology, dermatology and respiratory medicine. Conversely, only marginal increases in mortality and morbidity were evident for MBL., Conclusions: MGUS and MBL are generally considered to be relatively benign, since most individuals with monoclonal immunoglobulins never develop a B-cell malignancy or any other monoclonal protein-related organ/tissue-related disorder. Nonetheless, our findings offer strong support for the view that in some individuals, monoclonal gammopathy has the potential to cause systemic disease resulting in wide-ranging organ/tissue damage and excess mortality., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
24. Factor H Autoantibodies and Complement-Mediated Diseases.
- Author
-
Zhang Y, Ghiringhelli Borsa N, Shao D, Dopler A, Jones MB, Meyer NC, Pitcher GR, Taylor AO, Nester CM, Schmidt CQ, and Smith RJH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Atypical Hemolytic Uremic Syndrome blood, Atypical Hemolytic Uremic Syndrome epidemiology, Atypical Hemolytic Uremic Syndrome genetics, Biomarkers blood, Child, Child, Preschool, Complement C3b Inactivator Proteins genetics, Complement Factor H immunology, Epitopes, Female, Gene Deletion, Genetic Predisposition to Disease, Glomerulonephritis blood, Glomerulonephritis epidemiology, Glomerulonephritis genetics, Humans, Infant, Male, Middle Aged, Paraproteinemias blood, Paraproteinemias epidemiology, Paraproteinemias genetics, Phenotype, Prevalence, Retrospective Studies, United States epidemiology, Young Adult, Atypical Hemolytic Uremic Syndrome immunology, Autoantibodies blood, Glomerulonephritis immunology, Paraproteinemias immunology
- Abstract
Factor H (FH), a member of the regulators-of-complement-activation (RCA) family of proteins, circulates in human plasma at concentrations of 180-420 mg/L where it controls the alternative pathway (AP) of complement in the fluid phase and on cell surfaces. When the regulatory function of FH is impaired, complement-mediated tissue injury and inflammation occur, leading to diseases such as atypical hemolytic uremic syndrome (a thrombotic microangiopathy or TMA), C3 glomerulopathy (C3G) and monoclonal gammopathy of renal significance (MGRS). A pathophysiological cause of compromised FH function is the development of autoantibodies to various domains of the FH protein. FH autoantibodies (FHAAs) are identified in 10.9% of patients with aHUS, 3.2% of patients with C3G, and rarely in patients with MGRS. The phenotypic variability of FHAA-mediated disease reflects both the complexity of FH and the epitope specificity of FHAA for select regions of the native protein. In this paper, we have characterized FHAA epitopes in a large cohort of patients diagnosed with TMA, C3G or MGRS. We explore the epitopes recognized by FHAAs in these diseases and the association of FHAAs with the genetic deletion of both copies of the CFHR1 gene to show how these disease phenotypes are associated with this diverse spectrum of autoantibodies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Zhang, Ghiringhelli Borsa, Shao, Dopler, Jones, Meyer, Pitcher, Taylor, Nester, Schmidt and Smith.)
- Published
- 2020
- Full Text
- View/download PDF
25. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact.
- Author
-
Zimran A, Ruchlemer R, and Revel-Vilk S
- Subjects
- Adult, Comorbidity, Disease Management, Enzyme Replacement Therapy, Female, Gaucher Disease drug therapy, Gaucher Disease pathology, Humans, Paraproteinemias drug therapy, Paraproteinemias pathology, Young Adult, Gaucher Disease epidemiology, Paraproteinemias epidemiology
- Abstract
Patients with Gaucher disease (GD), a rare autosomal recessive glycosphingolipid storage disease, commonly present to hematologists with unexplained splenomegaly, thrombocytopenia, anemia, and bone symptoms. Patients with GD may develop other manifestations, such as autoimmune thrombocytopenia, monoclonal gammopathy, multiple myeloma, or, even more rarely, other hematological malignancies; sometimes they are first diagnosed during an assessment of those disorders. Although the diagnosis and management of patients with GD have significantly evolved over the last 30 years, some patients remain poor responders to GD-specific therapy, needing novel and investigational therapies. Ideally, patients with GD, like patients with other rare diseases, should be managed by a multidisciplinary team expert with the diverse clinical manifestations and potential GD-related or -unrelated comorbidities. The hematology community should be knowledgeable regarding the presentation and the variety of hematologic complications and comorbidities associated with Gaucher disease., Competing Interests: Conflict-of-interest disclosure: The Shaare Zedek Medical Center Gaucher Unit receives support from Sanofi/Genzyme for participation in the International Collaborative Gaucher Group Registry, from Takeda for the Gaucher Outcome Survey Registry, and Pfizer for the Taliglucerase Active Surveillance Registry. The unit also receives research grants from Takeda, Pfizer, Sanofi/Genzyme, and Centogene. A.Z. receives honoraria from Takeda, BioEvents, and Pfizer and consultancy fees from Takeda, Prevail Therapeutics, and AVROBIO. S.R.-V. receives speaker’s fees, travel support, and advisory fees from Takeda, Pfizer, Sanofi/Genzyme, and Prevail Therapeutics. R.R. has nothing to disclose. Off-label drug useDiscussion of off-table drug use: ambroxol., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
26. Frequency and characteristics of pruritus in patients with monoclonal gammopathy: a case-control study.
- Author
-
Devergne C, Kerspern H, Poizeau F, Eveillard JR, Carré JL, Misery L, Le Gall-Ianotto C, and Brenaut E
- Subjects
- Case-Control Studies, Humans, Pruritus epidemiology, Pruritus etiology, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias complications, Paraproteinemias epidemiology
- Published
- 2020
- Full Text
- View/download PDF
27. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls.
- Author
-
Rögnvaldsson S, Steingrímsson V, Turesson I, Björkholm M, Landgren O, and Yngvi Kristinsson S
- Subjects
- Humans, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Paraproteinemias diagnosis, Paraproteinemias epidemiology, Peripheral Nervous System Diseases epidemiology, Peripheral Nervous System Diseases etiology
- Published
- 2020
- Full Text
- View/download PDF
28. Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders.
- Author
-
Mert D, Merdin A, Çakar MK, Dal MS, and Altuntaş F
- Subjects
- Aged, Comorbidity, Female, HIV Infections blood, HIV Infections immunology, Hepatitis B blood, Hepatitis B Antigens immunology, Hepatitis B Core Antigens blood, Hepatitis B Core Antigens immunology, Hepatitis B Surface Antigens blood, Hepatitis B Surface Antigens immunology, Hepatitis B e Antigens blood, Hepatitis C Antibodies blood, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Male, Middle Aged, Multiple Myeloma epidemiology, Plasma Cells pathology, Retrospective Studies, Seroepidemiologic Studies, HIV Seroprevalence, Hepatitis B epidemiology, Hepatitis B Antigens blood, Hepatitis C epidemiology, Leukemia, Lymphocytic, Chronic, B-Cell epidemiology, Paraproteinemias epidemiology
- Abstract
Hepatitis B (HBV) and hepatitis C (HCV) viruses are hepatotropic and lymphotropic viruses that can proliferate either in lymphocytes and monocytes or hepatocytes.The aim of this study was to evaluate the seroprevalence of HBV, HCV, and human immunodeficiency virus (HIV) in patients with plasma cell disorders. We also aimed to compare patients with plasma cell disorders and chronic lymphocytic leukemia (CLL) in terms of HBV, HCV, and HIV seropositivity.This is a retrospective study. The patients who had patient file in the Multiple Myeloma Outpatient Unit of our hospital and were followed in our outpatient unit between January 1, 2012 and September 15, 2019, with diagnoses of either of the plasma cell disorders were included in the study. In addition, 272 CLL patients who were admitted to the Leukemia Outpatient Unit of our hospital were also enrolled in the study. The 2 disease groups were compared in terms of HBV, HCV, and HIV seropositivity.A statistically significant relationship was found between disease groups according to hepatitis B surface antigen (P < .05). Hepatitis B positivity were found to be more common in CLL patients. There was also a statistically significant relationship between the disease groups in terms of hepatitis B e antigen positivity (P = .001).We found that hepatitis B surface antigen positivity rate in CLL patients was higher than in patients with plasma cell disorders. Seroprevalence of HBV, HCV, and HIV was found to be very low in patients with plasma cell disorders.
- Published
- 2020
- Full Text
- View/download PDF
29. Diagnosis of paraproteinemic neuropathy: Room for improvement.
- Author
-
Karam C, Moshe-Lilie O, Chahin N, Ragole T, Medvedova E, and Silbermann R
- Subjects
- Amyloid, Amyloidogenic Proteins, Humans, Amyloidosis, POEMS Syndrome diagnosis, POEMS Syndrome epidemiology, Paraproteinemias complications, Paraproteinemias diagnosis, Paraproteinemias epidemiology
- Abstract
Objective: To report our institutional experience with paraproteinemic neuropathy., Methods: We reviewed the charts of patients evaluated at our tertiary, academic neuromuscular clinic for neuropathy between 2017 and 2019 and selected those with a serum monoclonal protein. We collected patients' characteristics and reviewed their initial diagnoses and eventual outcomes., Results: Fifty-four of 410 patients with neuropathy (13%) had a monoclonal protein. Of these patients, 25% had not had SPEP or IFE checked prior to referral. FLC was not checked in any of the patients prior to referral. The neuropathy was felt to be related to the monoclonal protein in 24 patients (44%). Ten patients (19%), had been misdiagnosed either because they were not screened for monoclonal protein or the monoclonal protein was considered a MGUS. AL amyloid and POEMS syndrome were the most frequently missed diagnoses., Conclusion: The diagnosis of paraproteinemic neuropathy was missed in nearly one in five patients in our cohort. Failure to accurately characterize a paraproteinemic neuropathy can have devastating effect on patients as some have underlying malignancies. We propose that testing serum free light chains in patients with peripheral neuropathy of unknow etiology, when SPEP/IFE are normal, may reduce the rate of misdiagnosis. Furthermore, patients with refractory CIDP should be carefully screened for POEMS syndrome., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
30. Epidemiological and immunochemical parameters of monoclonal plasma cell dyscrasias of 2121 cases in Algeria.
- Author
-
Belouni R, Allam I, Cherguelaine K, Berkani L, Belaid B, Berkouk Y, Nekkal S, Saidani M, Belhani M, Ghaffor M, and Djidjik R
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Algeria epidemiology, Child, Comorbidity, Female, Humans, Immunoglobulin Isotypes urine, Immunoglobulin Light Chains blood, Immunoglobulin Light Chains urine, Immunoglobulin M blood, Immunoglobulin M urine, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance blood, Monoclonal Gammopathy of Undetermined Significance epidemiology, Multiple Myeloma blood, Multiple Myeloma epidemiology, Multiple Myeloma urine, Paraproteinemias blood, Paraproteinemias urine, Paraproteins urine, Retrospective Studies, Sex Distribution, Young Adult, Immunoglobulin Isotypes blood, Paraproteinemias epidemiology, Paraproteins analysis
- Abstract
Background: Plasma cell dyscrasias (PCD) are a heterogeneous group of diseases characterized by the expansion of monoclonal bone marrow plasma cells that produce a monoclonal immunoglobulin (M-component)., Purpose: This is a retrospective study that describes the epidemiological, immunochemical features and etiology of monoclonal gammopathies diagnosed between 1998 and 2016 in the Teaching Hospital Beni-Messous of Algiers., Patients and Methods: 2121 cases of monoclonal gammopathies (MG) were collected during this period. Serum/urine protein electrophoresis, serum/urine immunofixation and serum free light chain measurements were used to demonstrate M protein., Results: The middle age of the patients at the time of the diagnosis were 62.96 ± 13.19 years with extremes ranging from 07 to 99 years. The study included 1013 (47, 76 %) men and 1108 (52, 23 %) women with a sex ratio 0,91. Isotypes repartition was: IgG (60.91 %), IgA (17.91 %), light chain (10.46 %), IgM (6.6 %), IgD (1.03 %) and IgE (0.09 %) of cases. The most frequent diagnosis was: Multiple Myeloma (55.20 %), followed by monoclonal gammopathy of undetermined significance (34.13 %)., Conclusion: In our study, two particularities were noted. There is no male predominance in Algerian PCD patients. Moreover, we observed a higher frequency of light chain multiple myeloma and lower frequency of IgM isotype compared to western studies., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
31. IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS.
- Author
-
Shelly S, Mills JR, Martinez-Thompson JM, Rofforth MM, Pittock SJ, Mandrekar J, Triplett JD, Mauermann M, Dubey D, and Klein CJ
- Subjects
- Cohort Studies, Humans, Motor Neuron Disease therapy, Paraproteinemias therapy, Polyradiculoneuropathy therapy, Treatment Outcome, Immunoglobulin M, Motor Neuron Disease complications, Paraproteinemias epidemiology, Polyradiculoneuropathy complications
- Abstract
Competing Interests: Competing interests: SJP: reports affiliation with Grifols, Alexion and Medimmune pharmaceuticals. He receives no personal compensation as all moneys are paid directly to Mayo Clinic; MM: reports receiving honorarium from Ackea related to TTR amyloidosis; DD Has received research support from Center of Multiple Sclerosis and Autoimmune Neurology, and Grifols pharmaceuticals. DD has consulted for UCB pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic; CJK reports receiving honorarium from Ackea related to TTR amyloidosis and Fabry disease. He has also been a consultant at Pfizer but received no personal compensation.
- Published
- 2020
- Full Text
- View/download PDF
32. A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria.
- Author
-
Nelson CA, Zhong CS, Hashemi DA, Ashchyan HJ, Brown-Joel Z, Noe MH, Imadojemu S, Micheletti RG, Vleugels RA, Wanat KA, Rosenbach M, and Mostaghimi A
- Subjects
- Aged, Cohort Studies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Multiple Myeloma epidemiology, Multiple Myeloma etiology, Necrobiotic Xanthogranuloma physiopathology, Necrobiotic Xanthogranuloma therapy, Paraproteinemias epidemiology, Retrospective Studies, Necrobiotic Xanthogranuloma diagnosis, Paraproteinemias etiology
- Abstract
Importance: Necrobiotic xanthogranuloma (NXG) is a non-Langerhans cell histiocytosis classically associated with paraproteinemia attributable to plasma-cell dyscrasias or lymphoproliferative disorders. Despite the morbidity of NXG, the literature is limited to case reports and small studies, and diagnostic criteria are lacking., Objective: To evaluate the characteristics of NXG and propose diagnostic criteria., Design, Setting, and Participants: This multicenter cross-sectional study was conducted at tertiary academic referral centers and followed by a systematic review and a consensus exercise. The multicenter cohort included patients with NXG diagnosed at the Brigham and Women's and Massachusetts General Hospitals (2000-2018), the University of Iowa Hospitals and Clinics (2000-2018), and the University of Pennsylvania Health System (2008-2018). The systematic review was conducted in 2018 and included patients with NXG identified in the Cochrane, Ovid EMBASE, PubMed, and Web of Science databases. The consensus exercise was conducted by 8 board-certified dermatologists to identify diagnostic criteria., Main Outcomes and Measures: Demographic factors, comorbidities, clinical features, and treatment response., Results: Of 235 included patients with NXG (34 from the multicenter cohort and 201 from the systematic review results), the mean (SD) age at presentation was 61.6 (14.2) years; 147 (62.6%) were female. Paraproteinemia was detected in 193 patients (82.1%), most often IgG-κ (117 patients [50.0%]). A malignant condition was detected in 59 patients (25.1%), most often multiple myeloma (33 patients [14.0%]). The overall rate of paraproteinemia and/or a malignant condition was 83.8% (197 patients). In the multicenter cohort, evolution of paraproteinemia into multiple myeloma was observed up to 5.7 years (median [range], 2.4 [0.1-5.7] years) after NXG presentation. Cutaneous lesions consisted of papules, plaques, and/or nodules, typically yellow or orange in color (113 of 187 [60.4%]) with a periorbital distribution (130 of 219 [59.3%]). The eye was the leading site of extracutaneous involvement (34 of 235 [14.5%]). In the multicenter cohort, intravenous immunoglobulin had the best treatment response rate (9 of 9 patients [100%]), followed by antimalarial drugs (4 of 5 patients [80%]), intralesional triamcinolone (6 of 8 patients [75%]), surgery (3 of 4 patients [75%]), chemotherapy (8 of 12 patients [67%]), and lenalidomide or thalidomide (5 of 8 patients [63%]). The consensus exercise yielded 2 major criteria, which were (1) clinical and (2) histopathological features consistent with NXG, and 2 minor criteria, consisting of (1) paraproteinemia, plasma-cell dyscrasia, and/or other associated lymphoproliferative disorder and (2) periorbital distribution of cutaneous lesions. In the absence of foreign body, infection, or another identifiable cause, fulfillment of both major and at least 1 minor criterion were proposed to establish the diagnosis of NXG., Conclusions and Relevance: Necrobiotic xanthogranuloma is a multisystem disorder associated with paraproteinemia and malignant conditions. The proposed diagnostic criteria may advance clinical research and should be validated.
- Published
- 2020
- Full Text
- View/download PDF
33. Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study.
- Author
-
Fenton A, Chinnadurai R, Gullapudi L, Kampanis P, Dasgupta I, Ritchie J, Harding S, Ferro CJ, Kalra PA, Taal MW, and Cockwell P
- Subjects
- Aged, Aged, 80 and over, Albuminuria, Cohort Studies, Comorbidity, Creatinine metabolism, Disease Progression, Female, Glomerular Filtration Rate, Humans, Immunoglobulin Light Chains, Kidney Failure, Chronic metabolism, Kidney Failure, Chronic therapy, Kidney Transplantation, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance metabolism, Paraproteinemias epidemiology, Proportional Hazards Models, Prospective Studies, Renal Dialysis, Renal Insufficiency, Chronic metabolism, United Kingdom epidemiology, Kidney Failure, Chronic epidemiology, Monoclonal Gammopathy of Undetermined Significance epidemiology, Mortality, Renal Insufficiency, Chronic epidemiology
- Abstract
Background: In studies including the general population, the presence of non-malignant monoclonal gammopathy (MG) can be causally associated with kidney damage and shorter survival. We assessed whether the presence of an MG is associated with a higher risk of kidney failure or death in individuals with chronic kidney disease (CKD)., Methods and Findings: Data were used from 3 prospective cohorts of individuals with CKD (not on dialysis or with a kidney transplant): (1) Renal Impairment in Secondary Care (RIISC, Queen Elizabeth Hospital and Heartlands Hospital, Birmingham, UK, N = 878), (2) Salford Kidney Study (SKS, Salford Royal Hospital, Salford, UK, N = 861), and (3) Renal Risk in Derby (RRID, Derby, UK, N = 1,739). Participants were excluded if they had multiple myeloma or any other B cell lymphoproliferative disorder with end-organ damage. Median age was 71.0 years, 50.6% were male, median estimated glomerular filtration rate was 42.3 ml/min/1.73 m2, and median urine albumin-to-creatinine ratio was 3.4 mg/mmol. All non-malignant MG was identified in the baseline serum of participants of RIISC. Further, light chain MG (LC-MG) was identified and studied in participants of RIISC, SKS, and RRID. Participants were followed up for kidney failure (defined as the initiation of dialysis or kidney transplantation) and death. Associations with the risk of kidney failure were estimated by competing-risks regression (handling death as a competing risk), and associations with death were estimated by Cox proportional hazards regression. In total, 102 (11.6%) of the 878 RIISC participants had an MG. During a median follow-up time of 74.0 months, there were 327 kidney failure events and 202 deaths. The presence of MG was not associated with risk of kidney failure (univariable subhazard ratio [SHR] 0.97 [95% CI 0.68 to 1.38], P = 0.85; multivariable SHR 1.16 [95% CI 0.80 to 1.69], P = 0.43), and although there was a higher risk of death in univariable analysis (hazard ratio [HR] 2.13 [95% CI 1.49 to 3.02], P < 0.001), this was not significant in multivariable analysis (HR 1.37 [95% CI 0.93 to 2.00], P = 0.11). Fifty-five (1.6%) of the 3,478 participants from all 3 studies had LC-MG. During a median follow-up time of 62.5 months, 564 of the 3,478 participants progressed to kidney failure, and 803 died. LC-MG was not associated with risk of kidney failure (univariable SHR 1.07 [95% CI 0.58 to 1.96], P = 0.82; multivariable SHR 1.42 [95% CI 0.78 to 2.57], P = 0.26). There was a higher risk of death in those with LC-MG in the univariable model (HR 2.51 [95% CI 1.59 to 3.96], P < 0.001), but not in the multivariable model (HR 1.49 [95% CI 0.93 to 2.39], P = 0.10). An important limitation of this work was that only LC-MG, rather than any MG, could be identified in participants from SKS and RRID., Conclusions: The prevalence of MG was higher in this CKD cohort than that reported in the general population. However, the presence of an MG was not independently associated with a significantly higher risk of kidney failure or, unlike in the general population, risk of death., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: PC has consulted for and advised the Binding Site, who produce the Freelite assay that has been used to measure the LC MGUS reported in this paper, and who carried out the intact immunoglobulin assays. SH is on the Board of Directors for The Binding Site who produce the Freelite assay used in this paper. MWT is a member of the Editorial Board of PLOS Medicine.
- Published
- 2020
- Full Text
- View/download PDF
34. Prognostic significance of monoclonal gammopathy in diffuse large B-cell lymphoma.
- Author
-
Papageorgiou SG, Thomopoulos TP, Spathis A, Bouchla A, Glezou I, Stavroulaki G, Gkontopoulos K, Bazani E, Foukas PG, and Pappa V
- Subjects
- Disease Management, Female, Humans, Incidence, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse therapy, Male, Paraproteinemias diagnosis, Paraproteinemias epidemiology, Patient Outcome Assessment, Prognosis, Public Health Surveillance, Rituximab administration & dosage, Rituximab adverse effects, Rituximab therapeutic use, Lymphoma, Large B-Cell, Diffuse complications, Lymphoma, Large B-Cell, Diffuse epidemiology, Paraproteinemias complications
- Published
- 2019
- Full Text
- View/download PDF
35. Immunoglobulin abnormalities in 1677 solid organ transplant recipients. Implications for posttransplantation follow-up.
- Author
-
Sečník P Jr, Jabor A, Lavríková P, Sečník J, Malíková P, Pokorná E, and Franeková J
- Subjects
- Adult, Algorithms, Cohort Studies, Czech Republic epidemiology, Female, Follow-Up Studies, Graft Rejection epidemiology, Graft Rejection mortality, Humans, Male, Mass Screening, Middle Aged, Paraproteinemias epidemiology, Paraproteinemias mortality, Postoperative Complications epidemiology, Postoperative Complications mortality, Risk, Survival Analysis, Transplantation, Homologous, Graft Rejection diagnosis, Organ Transplantation, Paraproteinemias diagnosis, Postoperative Complications diagnosis
- Abstract
Background: Posttransplant lymphoproliferative disorder (PTLD) is a severe complication of solid organ transplantation (SOT). However, there is no consensus on PTLD screening methods. Gammopathies (GP), which occur in 10-25% of SOT recipients, have been linked to subsequent development of PTLD. Therefore, GP detection methods, such as serum protein electrophoresis (SPE), serum protein immunofixation (SIFE), urine protein immunofixation (UIFE) and the quantitative measurement of serum free light chains (SFLC) are candidate methods for PTLD screening., Objective: We aimed to assess the frequency of PTLD and GP, association of GP with subsequent PTLD, allograft loss or death and the diagnostic performance of SPE/SIFE in PTLD screening. The main objective was to explore, whether GP detection methods can be used to enhance the efficiency of PTLD screening and to formulate a concise algorithm for posttransplantation (post-Tx) follow-up., Methods: We performed a cohort study on 1677 SOT recipients with SPE/SIFE data who underwent kidney, liver, heart, pancreas, Langerhans islets or multiple organ transplantation at the Institute of Clinical and Experimental Medicine between 1966 and 2015. The median (IQR) of follow-up time was 8.0 (4.0-12.0) years., Results: The frequencies of PTLD and GP in SOT recipients were 2.8% and 6.4%, respectively. The frequencies of transient GP, GP of undetermined significance and malignant GP were 33%, 63% and 4% respectively. The median time between SOT and GP detection was 2.0 (interquartile range 1.0-7.0) years. GP was associated with a significantly higher risk of PTLD, allograft loss and death, with hazard ratios (95% confidence intervals) of a 6.06 (2.51-14.64), 2.61 (1.49-4.6) and 1.99 (1.2-3.3), respectively. Additionally, GP was associated with 2.98-fold increased risk of allograft loss in kidney transplant patients. SPE diagnostic sensitivity and specificity for PTLD were 14.8% and 93.9%, respectively. PTLD was diagnosed more often and earlier if SPE/SIFE was included in the post-Tx follow-up., Conclusions: GP after SOT is associated with a high risk of PTLD, allograft loss and poor survival. The combination of SPE, SIFE, SFLC and UIFE is optimal for GP detection. These methods aid in identifying patients who are at risk for PTLD or allograft damage and should be included in regular post-Tx follow-up., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
36. Demystifying Biclonal Gammopathy: A Pathologist's Perspective.
- Author
-
Sharma S, Gupta P, Aggarwal R, Malhotra P, Minz RW, and Bansal F
- Subjects
- Aged, Aged, 80 and over, Electrophoresis, Female, Humans, Immunoglobulin A blood, Immunoglobulin G blood, Incidence, India epidemiology, Male, Middle Aged, Tertiary Care Centers, Paraproteinemias epidemiology, Paraproteinemias pathology
- Abstract
Background: The production of 2 monoclonal proteins characterizes biclonal gammopathic manifestations (BGMs). The available medical literature from India is chiefly restricted to case reports., Objective: To study the incidence of BGMs in a tertiary care center in Chandigarh, India, during a 4-year period. We evaluated these cases further for their laboratory characteristics., Methods: We scrutinized the contents of a database containing information from the studied 4-year period. Cases reported as BGMs on serum protein electrophoresis (SPEP) and confirmed by serum immunofixation electrophoresis (SIFE) were included., Results: A total of 15 cases, from a cohort of 914 cases of monoclonal gammopathic manifestations (MGMs), were available. On SPEP, 2 M bands were observed in 12 cases. On SIFE, 4 cases were reported as being of true BGMs. The most common heavy-chain combination observed was immunoglobulin (Ig)A-IgG. Follow-up was available in 2 patients., Conclusion: Identification of BGMs increases diagnostic precision, despite that the treatment is similar to that for monoclonal gammopathic manifestations (MGMs). BGMs can be transitory and may be observed at presentation or during the disease course., (© American Society for Clinical Pathology 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
37. Scleromyxedema and lichen myxedematosus: Is it associated with viral hepatitis?
- Author
-
Chen KY, Tzeng IS, Lee YY, Ting SW, Chang YY, and Ng CY
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Comorbidity, Female, Hepatitis B epidemiology, Humans, Liver Diseases, Alcoholic epidemiology, Male, Middle Aged, Paraproteinemias epidemiology, Prevalence, Retrospective Studies, Scleromyxedema diagnosis, Scleromyxedema pathology, Severity of Illness Index, Skin pathology, Young Adult, Hepatitis C epidemiology, Scleromyxedema epidemiology
- Abstract
Scleromyxedema (SM) was previously known to be associated with monoclonal gammopathy. The association of SM and its counterpart lichen myxedematosus (LM) with chronic hepatitis has rarely been reported. We retrospectively reviewed medical records and histopathological reports of consecutive patients who presented at our department with the diagnosis of SM or LM from January 2001 to September 2017. The patients' demographic details, cutaneous presentation, associated underlying diseases and hepatitic profile were studied and compared with previous published cases. In all, 28 patients were enrolled, including one SM, 19 LM and eight atypical LM. Of the patients, 50% (n = 14/28) had hepatitis. Of these, 21.4% (n = 6/28) had hepatitis C, 10.7% (n = 3/28) hepatitis B, 7.1% (n = 2/28) concurrent hepatitis B and C, whereas 10.7% (n = 3/28) had alcoholic liver disease. The prevalence of hepatitis C in our patients was 6.5-times higher than that of the general population (28.6% vs 4.4%) and the prevalence of hepatitis B was similar (17.9% vs 17.3%). Polyclonal gammopathy was found in 28.6% (n = 8/28) of the patients and monoclonal gammopathy was found in 7.1% (n = 2/28). The extent of clonality did not correlate with disease severity. Our study did not notice a significant association with monoclonal gammopathy but the prevalence of hepatitis C was found to increase 6.5-times in these patients compared with the general population. We recommend dermatologists to be aware of hepatitis investigations in such patients and future studies are warranted to understand the mechanism behind such association., (© 2019 Japanese Dermatological Association.)
- Published
- 2019
- Full Text
- View/download PDF
38. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.
- Author
-
Kumar S, Larson DR, Dispenzieri A, Therneau TM, Murray DL, Leif Bergsagel P, Kyle RA, and Vincent Rajkumar S
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Disease Susceptibility, Female, Humans, Immunoglobulin Light Chains blood, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Monoclonal Gammopathy of Undetermined Significance etiology, Myeloma Proteins, Paraproteinemias blood, Paraproteinemias diagnosis, Population Surveillance, Risk Assessment, Risk Factors, Clonal Evolution genetics, Immunoglobulin Light Chains genetics, Paraproteinemias epidemiology, Paraproteinemias etiology
- Abstract
Monoclonal gammopathies (MG) constitute a spectrum of disorders starting from a monoclonal gammopathy of undetermined significance (MGUS) to active disease requiring therapy such as multiple myeloma. MG are characterized by proliferation of clonal plasma cells (PC) secreting a monoclonal protein either as intact immunoglobulin or free kappa or lambda free light chains (FLC). We hypothesized that a polyclonal elevation of serum FLC may indicate an inflammatory state that precedes development of MG. We studied 15,630 individuals from Olmsted county, who did not have MGUS based on baseline screening studies. At a median follow-up of 18.1 years, 264 patients had developed a clonal PC disorder; 252 with MGUS, 1 with SMM, 8 with MM, and 3 with amyloidosis, translating to an annual incidence of development of a MG of 0.1%. We examined the baseline polyclonal ΣFLC (kappa + lambda FLC) from the initial screening and grouped them into deciles. The highest decile group had a 2.6-fold (95% CI; 1.8, 3.7) increase in the risk of developing a MG, P < 0.001. We demonstrate for the first time, the increased risk of developing MG in patients with elevated serum FLC, suggesting that an underlying inflammatory state may play an etiologic role.
- Published
- 2019
- Full Text
- View/download PDF
39. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
- Author
-
Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, and Kumar SK
- Subjects
- Aged, Biomarkers, Bone Marrow pathology, Bone Marrow Cells pathology, Disease Progression, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Monoclonal Gammopathy of Undetermined Significance mortality, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Paraproteinemias mortality, Retrospective Studies, Multiple Myeloma epidemiology, Paraproteinemias epidemiology
- Abstract
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). There is a lack of data regarding impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes. Patients with prior diagnosis of MGUS, SMM, or PC from 1973 to 2015 (cases) were identified from our institution's database and compared to those without a known MG (controls). The primary outcome of interest was overall survival (OS). Multivariate analysis was performed to ascertain factors impacting all-cause mortality. We identified 774 patients with a prior diagnosis of MGUS, SMM or SPC (cases) and a control population (1:2) matched for the year of diagnosis (n = 1548). After a median follow-up of 81 months, the cases showed a longer median OS than the controls (71 months vs. 56 months). The improved OS was limited to those with a known prior diagnosis of SMM (80 months) and SPC (95 months), compared to MGUS (60 months). Multivariable analysis revealed that MM patients with known prior MG had less overall mortality than those without, and this was limited to prior SMM/SPC group (HR 0.68, 95% CI: 0.50-0.93), as compared to the MGUS group (HR 0.83, 95% CI: 0.66-1.05).
- Published
- 2019
- Full Text
- View/download PDF
40. [Serum protein electrophoresis: study of 410 electrophoretic profiles].
- Author
-
Bouayadi O, Bensalah M, Rahmani N, Assoufi S, and Choukri M
- Subjects
- Adolescent, Adult, Agammaglobulinemia diagnosis, Agammaglobulinemia epidemiology, Aged, Aged, 80 and over, Child, Child, Preschool, Cross-Sectional Studies, Female, Hospitals, University, Humans, Hypoalbuminemia epidemiology, Infant, Inflammation epidemiology, Male, Middle Aged, Nephrotic Syndrome diagnosis, Nephrotic Syndrome epidemiology, Paraproteinemias epidemiology, Young Adult, Blood Protein Electrophoresis methods, Hypoalbuminemia diagnosis, Inflammation diagnosis, Paraproteinemias diagnosis
- Abstract
Serum protein electrophoresis (SPE) is a routine analysis in the daily practice of a medical biology laboratory. This study aimed to analyze the different electrophoretic profiles seen in our current practice. We conducted a cross-sectional study of 410 serum samples collected during the routine analyses in the Laboratory of Biochemistry at the University Hospital Mohammed VI in Oujda. Serum protein electrophoresis was performed using automated instrument CAPILLARYS 2 FLEX-PIERCING, SEBIA. 241 sera from women and 169 sera from men were collected. Patients were aged between 1-91 years, with an average age of 49 years; 19.5% of SPEs were normal, hypoalbuminemia was found in 34% of cases, chronic inflammatory syndrome in 19.5% of cases, nephrotic syndrome in 2% of cases, 5.8% of our patients had betagamma block, hypogammaglobulinemia was found in 8.5% of cases and 29 monoclonal peaks were noted, bisalbuminemia was found in 2 patients. Out of 410 collections: 92 immunofixations were performed, of whom 23 were positive (showing monoclonal gammopathy). This study highlights the variability in prescribing serum protein electrophoresis as well as the importance of clinical data for a better interpretation., Competing Interests: Les auteurs ne déclarent aucun conflit d'intérêts.
- Published
- 2019
- Full Text
- View/download PDF
41. Erythema elevatum diutinum: a case report and review of literature.
- Author
-
Doktor V, Hadi A, Hadi A, Phelps R, and Goodheart H
- Subjects
- Comorbidity, Dapsone therapeutic use, Folic Acid Antagonists therapeutic use, Humans, Male, Middle Aged, Arthritis, Rheumatoid epidemiology, HIV Infections epidemiology, Neoplasms epidemiology, Paraproteinemias epidemiology, Vasculitis, Leukocytoclastic, Cutaneous drug therapy, Vasculitis, Leukocytoclastic, Cutaneous epidemiology
- Abstract
Erythema elevatum diutinum (EED) is a rare cutaneous leukocytoclastic vasculitis thought to be related to increased levels of circulating antibodies. It has been shown to be associated with HIV infection, tuberculosis, as well as various autoimmune diseases. A retrospective review of all cases of EED indexed in PubMed between 1990 and 2014 was performed. Inclusion criteria for articles was availability of full text in English and a biopsy-confirmed diagnosis of EED. All other articles were excluded. Cases were stratified by age and anatomic location of the lesions. Treatment response was coded as "complete," "partial," and "none." A total of 133 cases of EED with 381 lesions detailed in case reports and case series were included. Twenty-one cases were associated with HIV. Of 47 patients with reported paraproteinemias, IgA paraproteinemia was found in 57.45%, IgG paraproteinemia in 29.8%, IgM paraproteinemia in 10.6%, and IgD paraproteinemia in 2.1% of cases. Of 40 (30.1%) patients with reported comorbid autoimmune disease, rheumatoid arthritis was associated with 10 cases. Cancer was found to be associated with 9.77% of cases. Seventy-five patients were treated with dapsone, with 36 (48%) achieving complete treatment response, 24 (32%) achieving partial response, and seven (9.3%) achieving no response. Keeping the clinical associations of EED in mind, especially malignancy, is critical in management of the disease. More structured studies need to take place in order to fully define the mechanisms and strength of these associations., (© 2018 The International Society of Dermatology.)
- Published
- 2019
- Full Text
- View/download PDF
42. [Primary plasma cell leukemia. Report of five cases].
- Author
-
Mendoza MG, Valladares X, Roa M, Reyes M, Osorio R, Undurraga MS, Legües ME, Cabrera ME, and Peña C
- Subjects
- Adult, Blood Cell Count, Calcium blood, Chile epidemiology, Creatinine blood, Cytogenetic Analysis, Female, Flow Cytometry methods, Humans, In Situ Hybridization, Fluorescence, Leukemia, Plasma Cell pathology, Leukemia, Plasma Cell therapy, Male, Middle Aged, Paraproteinemias epidemiology, Paraproteinemias genetics, Paraproteinemias pathology, Retrospective Studies, Survival Analysis, Treatment Outcome, Leukemia, Plasma Cell epidemiology, Leukemia, Plasma Cell genetics
- Abstract
Background: Primary plasma cell leukemia (pPCL) is uncommon, aggressive and has a different biology than multiple myeloma (MM)., Aim: To report the features of patients with pPCL., Material and Methods: Review of databases of the Hematology Department and the Hematology laboratory., Results: Of 178 patients with monoclonal gammopathies, five (2.8%) patients aged 33 to 64 years (three females) had a pPCL. The mean hemoglobin was 7.3 g/dL, the mean white blood cell count was 52,500/mm3, with 58% plasma cells, and the mean platelet count was 83,600/mm3. The mean bone marrow infiltration was 89%, LDH was 2,003 IU/L, serum calcium was 13 mg/dL, and creatinine 1.5 mg/dL. Two patients had bone lesions. Three were IgG, one IgA lambda and one lambda light chain. CD20 was positive in one, CD56 was negative in all and CD117 was negative in 3 cases. By conventional cytogenetic analysis, two had a complex karyotype. By Fluorescence in situ Hybridization, one was positive for TP53 and another for t (11; 14). One patient did not receive any treatment, three patients received VTD PACE and one CTD. None underwent transplant. Three patients are alive. The mean survival was 14 months., Conclusions: These patients with pPCL were younger and had a more aggressive clinical outcome than in multiple myeloma.
- Published
- 2019
- Full Text
- View/download PDF
43. Evaluation of Serum Free Light Chain in Diagnosis and Monitoring of Plasma Cell Disorders.
- Author
-
Ansari AA, Tipu HN, Ahmed D, and Farhan M
- Subjects
- Adult, Aged, Cross-Sectional Studies, Female, Granuloma, Plasma Cell epidemiology, Humans, Male, Middle Aged, Multiple Myeloma epidemiology, Pakistan epidemiology, Paraproteinemias epidemiology, Predictive Value of Tests, Reproducibility of Results, Sensitivity and Specificity, Electrophoresis methods, Enzyme-Linked Immunosorbent Assay methods, Granuloma, Plasma Cell diagnosis, Immunoglobulin Light Chains blood, Multiple Myeloma diagnosis, Paraproteinemias diagnosis, Plasma Cells pathology
- Abstract
Objective: To determine diagnostic accuracy of serum free light chain assay compared to serum and urine protein electrophoresis in plasma cell disorders., Study Design: Descriptive cross-sectional study., Place and Duration of Study: This study was conducted in the Immunology Department, Armed Forces institute of Pathology (AFIP), Rawalpindi, from May 2017 to May 2018., Methodology: Patients referred to AFIP for diagnosis of plasma cell disorders or for monitoring while receiving treatment were included in study. They were tested for serum protein electrophoresis (SPE), urine protein electrophoresis (UPE), immunofixation (IF), and serum free light chain assay (sFLC). IF was used as the reference standard. Test results were compared in terms of sensitivity, specificity, positive or negative predictive value, and accuracy index., Results: During the study period 220 patients were tested for plasma cell disorders. One hundred and sixty-seven patients tested positive. One hundred twenty-nine patients had multiple myeloma, 13 plasmacytoma, 11 monoclonal gammopathy of undetermined significance, 6 amyloidosis, 6 POEMS, and 2 Waldenstrom macroglobulinemia. SPE had a sensitivity of 70.5%, specificity of 100%; sFLC had a sensitivity of 87%, specificity of 81%; and UPE had a sensitivity of 23.5%, specificity of 97%. Accuracy index was 80.5% for SPE, 85% for sFLC, and 54% for UPE. When taken together, SPE and UPE had a combined sensitivity of 72%, specificity 97%, and accuracy index 80.5%. SPE and sFLC had combined sensitivity of 98.6%, specificity 84.3%, and accuracy index 94%., Conclusion: Combination of SPE and sFLC had the highest sensitivity and accuracy index for diagnosis and monitoring of plasma cell disorders compared with conventional tests.
- Published
- 2019
- Full Text
- View/download PDF
44. Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature.
- Author
-
Jachiet M, Harel S, Saussine A, Battistella M, Rybojad M, Asli B, Bengoufa D, Mahevas T, Bessis D, Galicier L, Schmutz JL, Hadj-Rabia S, Boutboul D, Lebbé C, Bagot M, Malphettes M, Lipsker D, Fermand JP, Bouaziz JD, and Arnulf B
- Subjects
- Adult, Age Distribution, Aged, Biopsy, Needle, Comorbidity, Female, Humans, Immunohistochemistry, Incidence, Male, Middle Aged, Prognosis, Sampling Studies, Severity of Illness Index, Sex Distribution, Cutis Laxa epidemiology, Cutis Laxa pathology, Paraproteinemias epidemiology, Paraproteinemias pathology
- Published
- 2018
- Full Text
- View/download PDF
45. [Epidemiology of monoclonal gammopathies].
- Author
-
Decaux O
- Subjects
- Humans, Immunoglobulin G, Multiple Myeloma epidemiology, Paraproteinemias epidemiology
- Abstract
Competing Interests: O. Decaux déclare avoir des liens d’intérêts (essais, activités de conseil, conférences, prise en charge lors de congrès) avec Amgen, Novartis, Takeda, Janssen, Celgene, The Binding Site, Sebia et Siemens.
- Published
- 2018
46. Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma.
- Author
-
Chernova NG, Soboleva NP, Mariina SA, Sidorova YV, Sinitsyna MN, Dvirnyk VN, Badmazhapova DS, Vinogradova YE, Zvonkov EE, and Savchenko VG
- Subjects
- Adult, Agammaglobulinemia blood, Agammaglobulinemia epidemiology, Aged, Aged, 80 and over, Female, Humans, Hypergammaglobulinemia blood, Hypergammaglobulinemia epidemiology, Immunoblastic Lymphadenopathy blood, Immunoblastic Lymphadenopathy epidemiology, Immunoglobulin Light Chains blood, Lymphoma, T-Cell blood, Lymphoma, T-Cell epidemiology, Male, Middle Aged, Paraproteinemias blood, Paraproteinemias epidemiology, Agammaglobulinemia complications, Hypergammaglobulinemia complications, Immunoblastic Lymphadenopathy complications, Lymphoma, T-Cell complications, Paraproteinemias complications
- Abstract
Aim: The aim of the study was to characterize quantitative and qualitative immunoglobulinopathies in patients with AITL at the onset of the disease., Materials and Methods: 55 patients with newly diagnosed AITL were enrolled in the study, the male/female ratio was 30/25; median age was 61 (29-81) years. Diagnosis was based on standard WHO criteria. Immunochemical studies of blood serum included serum protein electrophoresis/immunofixation, nephelometric quantification of total immunoglobulins, serum free light chain assay., Results: Quantitative and qualitative immunoglobulinopathies were determined in 49 (89,1%) of 55 pts. Quantitative immunoglobulinopathies were revealed in 47 (85.5%) of 55 cases, qualitative - in 14 (25,5%). Combination quantitative and qualitative immunoglobulinopathies was observed in 12 (21,8%) of 55 pts. The detected immunoglobulinopathies were divided into 4 groups: polyclonal hypergammaglobulinaemia, hypogammaglobulinaemia, oligoclonal gammapathy, and monoclonal gammapathy. Polyclonal hypergammaglobulinaemia was marked in 41 (74.5%) of 55 pts, elevated level of IgG was determined in 27 (49,15%) of 55 cases, IgM - in 18 (32,7%) and IgA - in 21 (38.2%). Interestingly, polyclonal IgE hypergammaglobulinaemia was detected in 12 (48,0%) of 25 cases of performed studies. Hypogammaglobulinaemia was detected in 8 (14,5%) of 55 cases. Oligoclonal gammapathy was determined in 4 (7.3%) of 55 pts. Monoclonal gammapathy was revealed in 11 (20,0%) of 55 cases. The amount of monoclonal immunoglobulin varied from 2.6 to 14.1 g/l. Monoclonal immunoglobulin Gk was detected in 5 of 11 pts, Gλ - in 2, Mλ - in 2, Mk - in 2. Monoclonal gammapathy was accompanied by polyclonal hypergammaglobulinaemia in 9 of 11 cases, hypogammaglobulinaemia - in 2., Conclusion: Quantitative and qualitative immunoglobulinopathies are observed in most patients at the onset of AITL. Quantitative abnormalities were determined more often than qualitative. Monoclonal gammapathy can be a manifestation of lymphoproliferation and other concomitant disorders. The prognostic value of immunochemical parameters is still unclear and requires dynamic observation and study.
- Published
- 2018
- Full Text
- View/download PDF
47. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
- Author
-
Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, and Hájek R
- Subjects
- Adult, Aged, Aged, 80 and over, Czech Republic epidemiology, Female, Humans, Male, Middle Aged, Multiple Myeloma diagnosis, Neoplasm Staging, Paraproteinemias diagnosis, Paraproteinemias epidemiology, Practice Patterns, Physicians', Registries, Retrospective Studies, Risk Assessment, Risk Factors, Survival Analysis, Multiple Myeloma epidemiology
- Abstract
This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting., (© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
48. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.
- Author
-
Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, and Sethi S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Autoantibodies blood, Autoimmune Diseases epidemiology, Child, Child, Preschool, Complement C3 genetics, Complement C3 Nephritic Factor analysis, Complement Factor H genetics, Complement System Proteins, Creatinine blood, Disease Progression, Female, Genetic Variation, Glucocorticoids therapeutic use, Hematuria epidemiology, Humans, Immunoglobulins blood, Immunosuppressive Agents therapeutic use, Infections epidemiology, Kidney Failure, Chronic epidemiology, Male, Middle Aged, Minnesota epidemiology, Nephrotic Syndrome epidemiology, Paraproteinemias epidemiology, Proteinuria epidemiology, Young Adult, Glomerulonephritis blood, Glomerulonephritis drug therapy, Glomerulonephritis genetics
- Abstract
Objective: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy., Patients and Methods: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study., Results: The mean age at diagnosis for the entire cohort was 40.4±22.3 years, with a median serum creatinine level and proteinuria value of 1.6 mg/dL (range: 0.3-14.7) (to convert to mmol/L, multiply by 0.0259) and 2605 mg/24 h (range: 233-24,165), respectively. Hematuria was present in 100 patients (87.7%). The C3 and C4 levels were low in 50 of 112 (44.6%) and 13 of 110 (11.8%) patients, respectively. A history of infection, positive autoimmune findings, and monoclonal gammopathy (MIg) were present in 33 of 114 (28.9%), 28 of 114 (24.6%), and 36 of 95 (37.9%) patients, respectively. However, 28 of 43 patients 50 years or older (65.1%) had MIg. A genetic variant in complement genes, C3 nephritic factor (C3Nef), and other autoantibodies was present in 26 of 70 (37.1%), 30 of 69 (43.5%), and 9 of 67 (13.4%) patients, respectively. Membranoproliferative and mesangial proliferative glomerulonephritis were the common patterns of injury. Patients without MIg were younger (mean age, 32.3±20.6 years), with a median serum creatinine level and proteinuria value of 1.4 mg/dL (range: 0.3-7.9) and 2450 mg/24 h (range: 250-24, 165) and with low C3 and C4 levels in 38 of 77 (49.4%) and 9 of 75 (12.0%) patients, respectively. Most patients received corticosteroids and other immunosuppressive drugs. In patients without MIg, at a median follow-up of 22.3 months (range: 0.1-201.1), the median serum creatinine level and proteinuria value were 1.4 mg/dL (range: 0.3-3.7) and 825.5 mg/24 h (range: 76-22, 603), and 7 patients (9.2%) had progression to end-stage renal disease., Conclusion: C3 glomerulopathy is a heterogeneous disease entity with complex triggering events and abnormalities of the alternative pathway of complement. The disease tends to be progressive and exhibits a variable response to immunosuppressive therapy., (Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
49. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum.
- Author
-
Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, James WD, Micheletti RG, Rosenbach M, and Mostaghimi A
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Arthritis, Rheumatoid epidemiology, Comorbidity, Female, Humans, Male, Middle Aged, Polycythemia Vera epidemiology, Pyoderma Gangrenosum diagnosis, Retrospective Studies, Spondylitis, Ankylosing epidemiology, United States epidemiology, Arthritis epidemiology, Inflammatory Bowel Diseases epidemiology, Neoplasms epidemiology, Paraproteinemias epidemiology, Pyoderma Gangrenosum epidemiology
- Abstract
Importance: Pyoderma gangrenosum is an inflammatory neutrophilic dermatosis. Current knowledge of this rare disease is limited owing to a lack of validated diagnostic criteria and large population studies., Objective: To evaluate the association of age with the clinical presentation and comorbidities of pyoderma gangrenosum., Design, Setting, and Participants: This was a multicenter retrospective cohort study performed at tertiary academic referral centers in urban settings. Adults (≥18 years) who were evaluated and diagnosed as having pyoderma gangrenosum at the Brigham and Women's and Massachusetts General Hospitals from 2000 to 2015 and the University of Pennsylvania Health System from 2006 to 2016 were included., Main Outcomes and Measures: Patient demographics, clinical features, medical comorbidities, and treatment., Results: Of the 356 validated cases of pyoderma gangrenosum included in the study, 267 (75%) were women and 284 (84.8%) were white. The mean (SD) age at presentation was 51.6 (17.7) years. Pathergy was recorded in 100 patients (28.1%). A total of 238 patients (66.9%) had associated medical comorbidities: inflammatory bowel disease in 146 patients (41.0%); inflammatory arthritis in 73 patients (20.5%); solid organ malignant neoplasms in 23 patients (6.5%); hematologic malignant neoplasms in 21 patients (5.9%); and hematologic disorders, specifically monoclonal gammopathy of undetermined significance, myelodysplastic syndrome, and polycythemia vera in 17 patients (4.8%). When stratified by age, pathergy was more common in patients 65 years or older (36.3% vs 24.3%; P = .02). Inflammatory bowel disease was the only medical comorbidity that was more common in patients younger than 65 years (47.7% vs 26.6%; P < .001), while a number of medical comorbidities were more common in those 65 years or older, including rheumatoid arthritis (13.3% vs 6.2%; P = .03), ankylosing spondylitis (1.8% vs 0%; P = .04), solid organ malignant neoplasms (13.3% vs 3.3%; P < .001), hematologic malignant neoplasms (9.7% vs 4.1%; P = .04), and the aforementioned hematologic disorders (10.6% vs 2.1%; P < .001)., Conclusions and Relevance: Although clinical presentation in this large cohort was similar between different age groups, disease associations varied by age. The findings of this study may allow for a more focused, age-specific evaluation of patients with pyoderma gangrenosum.
- Published
- 2018
- Full Text
- View/download PDF
50. Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival.
- Author
-
McIlroy G, Mytton J, Evison F, Yadav P, Drayson MT, Cook M, Pratt G, Cockwell P, and Pinney JH
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Fractures, Bone epidemiology, Fractures, Spontaneous epidemiology, Humans, Infant, Infant, Newborn, Kaplan-Meier Estimate, Male, Paraproteinemias epidemiology, Population Surveillance, Proportional Hazards Models, Risk, Survival Analysis, Young Adult, Fractures, Bone etiology, Fractures, Spontaneous etiology, Paraproteinemias complications, Paraproteinemias mortality
- Abstract
Pathological fractures are a common complication of plasma cell dyscrasias (PCD) and are associated with significant morbidity. Routine use of bisphosphonates over the past decade has aimed to reduce the risk of fractures in patients with multiple myeloma, but despite this, fractures continue to represent a significant burden of disease. In this study we report the fracture rate of hospital in-patients with PCD in England. Data from the national registry Hospital Episode Statistics between 2001 and 2015 were used to determine fracture rate and its effect on overall survival. Fracture rates were 17·8 times higher than the general population in the first year after admission with PCD, and remained elevated for up to 10 years after first admission. The increased fracture risk preceded the first admission with PCD and, conversely, the incidence of PCD increased after admission with one or more fractures. Overall survival is improving with PCD, however poorer survival is found in patients with a preceding fracture (Hazard ratio 1·20). Despite widespread bisphosphonate use, fractures remain common in PCD, and are associated with poorer outcomes., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.